BindingDB

null

SMILES COc1ccc(CN(CCN(C)C)c2ccccn2)cc1

InChI Key InChIKey=YECBIJXISLIIDS-UHFFFAOYSA-N

PDB links: 1 PDB ID matches this monomer.

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 4 hits for monomerid = 22567

Histamine H1 receptor(Homo sapiens (Human))
Vrije Universiteit Amsterdam

Curated by ChEMBL

BDBM22567(3H]pyrilamine | CHEMBL511 | Dorantamin | Mepyramin...)copy SMILEScopy InChI

Ki: 1.30nMAssay Description:Displacement of [3H]mepyramine from human wild type N-terminal hemagglutinin-tagged histamine H1 receptor expressed in HEK293T cells after 4 hrs by m...More data for this Ligand-Target Pair

PDB Reactome pathway KEGG
UniProtKB/SwissProt
DrugBank antibodypedia GoogleScholar

Purchase CHEMBL DrugBank MCE
KEGG PC cid PC sid PDB Patents Similars

Details Article
BindingDB Entry DOI: 10.7270/Q2G44S8ZPubMed DrugBank

Histamine H4 receptor(Homo sapiens (Human))
Vrije Universiteit Amsterdam

BDBM22567(3H]pyrilamine | CHEMBL511 | Dorantamin | Mepyramin...)copy SMILEScopy InChI

Ki: >1.00E+4nM ΔG°: >-7.09kcal/molepH: 7.4 T: 2°CAssay Description:Ligand displacement assays were performed on The SK-N-MC/hH4R cell homogenates. Retained radioactivity was determined by liquid scintillation countin...More data for this Ligand-Target Pair

PDB Reactome pathway KEGG
UniProtKB/SwissProt
DrugBank antibodypedia GoogleScholar

Purchase CHEMBL DrugBank MCE
KEGG PC cid PC sid PDB Patents Similars

Details Article
BindingDB Entry DOI: 10.7270/Q2KD1W6VPubMed

Histamine H1 receptor(Homo sapiens (Human))
Vrije Universiteit Amsterdam

Curated by ChEMBL

BDBM22567(3H]pyrilamine | CHEMBL511 | Dorantamin | Mepyramin...)copy SMILEScopy InChI

IC50: 13nMAssay Description:Inhibitory activity against human Histamine H1 receptorMore data for this Ligand-Target Pair

PDB Reactome pathway KEGG
UniProtKB/SwissProt
DrugBank antibodypedia GoogleScholar

Purchase CHEMBL DrugBank MCE
KEGG PC cid PC sid PDB Patents Similars

Details Article
BindingDB Entry DOI: 10.7270/Q2GT5PF7PubMed DrugBank

Histamine H1 receptor(Homo sapiens (Human))
Vrije Universiteit Amsterdam

Curated by ChEMBL

BDBM22567(3H]pyrilamine | CHEMBL511 | Dorantamin | Mepyramin...)copy SMILEScopy InChI

IC50: 10nMAssay Description:Inverse agonist activity at human wild-type histamine H1 receptor assessed as NF-kappaB activation after 48 hrs by luciferase reporter gene assayMore data for this Ligand-Target Pair

PDB Reactome pathway KEGG
UniProtKB/SwissProt
DrugBank antibodypedia GoogleScholar

Purchase CHEMBL DrugBank MCE
KEGG PC cid PC sid PDB Patents Similars

Details Article
BindingDB Entry DOI: 10.7270/Q2HQ415PPubMed DrugBank

Targets 7 ▿
- Histamine H1 receptor 34
- Hrh3 protein 3
- Histamine H3 receptor 2
- 5-hydroxytryptamine receptor 1A 1
- Histamine H4 receptor 1
- Potassium voltage-gated channel subfamily H member 2 1
- Bile salt export pump 1
Publications 32 ▿
- J Pharmacol Exp Ther 302: 328-36 (2002) 4
- Bioorg Med Chem Lett 21: 6274-80 (2011) 2
- J Med Chem 55: 7054-60 (2012) 2
- Eur J Pharmacol 311: 305-10 (1996) 2
- J Med Chem 60: 349-361 (2017) 2
- J Med Chem 57: 4543-57 (2014) 2
- Eur J Med Chem 63: 85-94 (2013) 2
- Eur J Biochem 224: 489-95 (1994) 2
- Bioorg Med Chem Lett 23: 1834-8 (2013) 2
- J Med Chem 54: 8195-206 (2011) 1
- Nat Chem Biol 1: 98-103 (2006) 1
- Bioorg Med Chem Lett 14: 4771-7 (2004) 1
- J Nat Prod 69: 432-5 (2006) 1
- Eur J Med Chem 92: 221-35 (2015) 1
- Biochem Pharmacol 45: 375-83 (1993) 1
- Life Sci 68: 29-39 (2000) 1
- J Recept Signal Transduct Res 15: 91-102 (1995) 1
- Bioorg Med Chem 18: 7675-99 (2010) 1
- Bioorg Med Chem 21: 2764-71 (2013) 1
- Drug Metab Dispos 40: 2332-41 (2012) 1
- J Pharmacol Exp Ther 314: 1310-21 (2005) 1
- Bioorg Med Chem Lett 10: 1277-9 (2000) 1
- Bioorg Med Chem 24: 1793-810 (2016) 1
- Bioorg Med Chem 25: 471-482 (2017) 1
- J Neurochem 55: 1612-6 (1990) 1
- Eur J Pharmacol 245: 291-5 (1993) 1
- Proc Natl Acad Sci U S A 75: 6290-4 (1978) 1
- J Med Chem 46: 5812-24 (2003) 1
- J Med Chem 48: 6887-96 (2005) 1
- Mol Pharmacol 55: 1101-7 (1999) 1
- Brain Res 304: 1-7 (1984) 1
- J Med Chem 59: 9047-9061 (2016) 1
Institutions 28 ▿
- [Vrije Universiteit Amsterdam, University of North Carolina at Chapel Hill] 4
- [Vrije Universiteit Amsterdam, University of North Carolina at Chapel Hill] 4
- [Glaxo Research & Development Ltd., Universit£ degli Studi di Siena, Université Libre de Bruxelles, Adamed Ltd., Broad Institute of MIT and Harvard, The University of Newcastle , University of Regensburg, University of Oxford, Jagiellonian University Medical College] 2
- [Glaxo Research & Development Ltd., Universit£ degli Studi di Siena, Université Libre de Bruxelles, Adamed Ltd., Broad Institute of MIT and Harvard, The University of Newcastle , University of Regensburg, University of Oxford, Jagiellonian University Medical College] 2
- [Glaxo Research & Development Ltd., Universit£ degli Studi di Siena, Université Libre de Bruxelles, Adamed Ltd., Broad Institute of MIT and Harvard, The University of Newcastle , University of Regensburg, University of Oxford, Jagiellonian University Medical College] 2
- [Glaxo Research & Development Ltd., Universit£ degli Studi di Siena, Université Libre de Bruxelles, Adamed Ltd., Broad Institute of MIT and Harvard, The University of Newcastle , University of Regensburg, University of Oxford, Jagiellonian University Medical College] 2
- [Glaxo Research & Development Ltd., Universit£ degli Studi di Siena, Université Libre de Bruxelles, Adamed Ltd., Broad Institute of MIT and Harvard, The University of Newcastle , University of Regensburg, University of Oxford, Jagiellonian University Medical College] 2
- [Glaxo Research & Development Ltd., Universit£ degli Studi di Siena, Université Libre de Bruxelles, Adamed Ltd., Broad Institute of MIT and Harvard, The University of Newcastle , University of Regensburg, University of Oxford, Jagiellonian University Medical College] 2
- [Glaxo Research & Development Ltd., Universit£ degli Studi di Siena, Université Libre de Bruxelles, Adamed Ltd., Broad Institute of MIT and Harvard, The University of Newcastle , University of Regensburg, University of Oxford, Jagiellonian University Medical College] 2
- [Glaxo Research & Development Ltd., Universit£ degli Studi di Siena, Université Libre de Bruxelles, Adamed Ltd., Broad Institute of MIT and Harvard, The University of Newcastle , University of Regensburg, University of Oxford, Jagiellonian University Medical College] 2
- [Glaxo Research & Development Ltd., Universit£ degli Studi di Siena, Université Libre de Bruxelles, Adamed Ltd., Broad Institute of MIT and Harvard, The University of Newcastle , University of Regensburg, University of Oxford, Jagiellonian University Medical College] 2
- [Mayo Foundation for Medical Education and Research and Mayo Clinic, Jagiellonian University Collegium Medicum, Pfizer Inc., Universit£ degli Studi di Urbino Carlo Bo, China Pharmaceutical University, Tom's of Maine, VU University Amsterdam, University of Bath, Janssen Research Foundation, TBA, Universite Libre de Bruxelles, Mayo Foundation, R.W. Johnson Pharmaceutical Research Institute, Institute of Organic Synthesis, AstraZeneca, Schering-Plough Research, University of Cambridge] 1
- [Mayo Foundation for Medical Education and Research and Mayo Clinic, Jagiellonian University Collegium Medicum, Pfizer Inc., Universit£ degli Studi di Urbino Carlo Bo, China Pharmaceutical University, Tom's of Maine, VU University Amsterdam, University of Bath, Janssen Research Foundation, TBA, Universite Libre de Bruxelles, Mayo Foundation, R.W. Johnson Pharmaceutical Research Institute, Institute of Organic Synthesis, AstraZeneca, Schering-Plough Research, University of Cambridge] 1
- [Mayo Foundation for Medical Education and Research and Mayo Clinic, Jagiellonian University Collegium Medicum, Pfizer Inc., Universit£ degli Studi di Urbino Carlo Bo, China Pharmaceutical University, Tom's of Maine, VU University Amsterdam, University of Bath, Janssen Research Foundation, TBA, Universite Libre de Bruxelles, Mayo Foundation, R.W. Johnson Pharmaceutical Research Institute, Institute of Organic Synthesis, AstraZeneca, Schering-Plough Research, University of Cambridge] 1
- [Mayo Foundation for Medical Education and Research and Mayo Clinic, Jagiellonian University Collegium Medicum, Pfizer Inc., Universit£ degli Studi di Urbino Carlo Bo, China Pharmaceutical University, Tom's of Maine, VU University Amsterdam, University of Bath, Janssen Research Foundation, TBA, Universite Libre de Bruxelles, Mayo Foundation, R.W. Johnson Pharmaceutical Research Institute, Institute of Organic Synthesis, AstraZeneca, Schering-Plough Research, University of Cambridge] 1
- [Mayo Foundation for Medical Education and Research and Mayo Clinic, Jagiellonian University Collegium Medicum, Pfizer Inc., Universit£ degli Studi di Urbino Carlo Bo, China Pharmaceutical University, Tom's of Maine, VU University Amsterdam, University of Bath, Janssen Research Foundation, TBA, Universite Libre de Bruxelles, Mayo Foundation, R.W. Johnson Pharmaceutical Research Institute, Institute of Organic Synthesis, AstraZeneca, Schering-Plough Research, University of Cambridge] 1
- [Mayo Foundation for Medical Education and Research and Mayo Clinic, Jagiellonian University Collegium Medicum, Pfizer Inc., Universit£ degli Studi di Urbino Carlo Bo, China Pharmaceutical University, Tom's of Maine, VU University Amsterdam, University of Bath, Janssen Research Foundation, TBA, Universite Libre de Bruxelles, Mayo Foundation, R.W. Johnson Pharmaceutical Research Institute, Institute of Organic Synthesis, AstraZeneca, Schering-Plough Research, University of Cambridge] 1
- [Mayo Foundation for Medical Education and Research and Mayo Clinic, Jagiellonian University Collegium Medicum, Pfizer Inc., Universit£ degli Studi di Urbino Carlo Bo, China Pharmaceutical University, Tom's of Maine, VU University Amsterdam, University of Bath, Janssen Research Foundation, TBA, Universite Libre de Bruxelles, Mayo Foundation, R.W. Johnson Pharmaceutical Research Institute, Institute of Organic Synthesis, AstraZeneca, Schering-Plough Research, University of Cambridge] 1
- [Mayo Foundation for Medical Education and Research and Mayo Clinic, Jagiellonian University Collegium Medicum, Pfizer Inc., Universit£ degli Studi di Urbino Carlo Bo, China Pharmaceutical University, Tom's of Maine, VU University Amsterdam, University of Bath, Janssen Research Foundation, TBA, Universite Libre de Bruxelles, Mayo Foundation, R.W. Johnson Pharmaceutical Research Institute, Institute of Organic Synthesis, AstraZeneca, Schering-Plough Research, University of Cambridge] 1
- [Mayo Foundation for Medical Education and Research and Mayo Clinic, Jagiellonian University Collegium Medicum, Pfizer Inc., Universit£ degli Studi di Urbino Carlo Bo, China Pharmaceutical University, Tom's of Maine, VU University Amsterdam, University of Bath, Janssen Research Foundation, TBA, Universite Libre de Bruxelles, Mayo Foundation, R.W. Johnson Pharmaceutical Research Institute, Institute of Organic Synthesis, AstraZeneca, Schering-Plough Research, University of Cambridge] 1
- [Mayo Foundation for Medical Education and Research and Mayo Clinic, Jagiellonian University Collegium Medicum, Pfizer Inc., Universit£ degli Studi di Urbino Carlo Bo, China Pharmaceutical University, Tom's of Maine, VU University Amsterdam, University of Bath, Janssen Research Foundation, TBA, Universite Libre de Bruxelles, Mayo Foundation, R.W. Johnson Pharmaceutical Research Institute, Institute of Organic Synthesis, AstraZeneca, Schering-Plough Research, University of Cambridge] 1
- [Mayo Foundation for Medical Education and Research and Mayo Clinic, Jagiellonian University Collegium Medicum, Pfizer Inc., Universit£ degli Studi di Urbino Carlo Bo, China Pharmaceutical University, Tom's of Maine, VU University Amsterdam, University of Bath, Janssen Research Foundation, TBA, Universite Libre de Bruxelles, Mayo Foundation, R.W. Johnson Pharmaceutical Research Institute, Institute of Organic Synthesis, AstraZeneca, Schering-Plough Research, University of Cambridge] 1
- [Mayo Foundation for Medical Education and Research and Mayo Clinic, Jagiellonian University Collegium Medicum, Pfizer Inc., Universit£ degli Studi di Urbino Carlo Bo, China Pharmaceutical University, Tom's of Maine, VU University Amsterdam, University of Bath, Janssen Research Foundation, TBA, Universite Libre de Bruxelles, Mayo Foundation, R.W. Johnson Pharmaceutical Research Institute, Institute of Organic Synthesis, AstraZeneca, Schering-Plough Research, University of Cambridge] 1
- [Mayo Foundation for Medical Education and Research and Mayo Clinic, Jagiellonian University Collegium Medicum, Pfizer Inc., Universit£ degli Studi di Urbino Carlo Bo, China Pharmaceutical University, Tom's of Maine, VU University Amsterdam, University of Bath, Janssen Research Foundation, TBA, Universite Libre de Bruxelles, Mayo Foundation, R.W. Johnson Pharmaceutical Research Institute, Institute of Organic Synthesis, AstraZeneca, Schering-Plough Research, University of Cambridge] 1
- [Mayo Foundation for Medical Education and Research and Mayo Clinic, Jagiellonian University Collegium Medicum, Pfizer Inc., Universit£ degli Studi di Urbino Carlo Bo, China Pharmaceutical University, Tom's of Maine, VU University Amsterdam, University of Bath, Janssen Research Foundation, TBA, Universite Libre de Bruxelles, Mayo Foundation, R.W. Johnson Pharmaceutical Research Institute, Institute of Organic Synthesis, AstraZeneca, Schering-Plough Research, University of Cambridge] 1
- [Mayo Foundation for Medical Education and Research and Mayo Clinic, Jagiellonian University Collegium Medicum, Pfizer Inc., Universit£ degli Studi di Urbino Carlo Bo, China Pharmaceutical University, Tom's of Maine, VU University Amsterdam, University of Bath, Janssen Research Foundation, TBA, Universite Libre de Bruxelles, Mayo Foundation, R.W. Johnson Pharmaceutical Research Institute, Institute of Organic Synthesis, AstraZeneca, Schering-Plough Research, University of Cambridge] 1
- [Mayo Foundation for Medical Education and Research and Mayo Clinic, Jagiellonian University Collegium Medicum, Pfizer Inc., Universit£ degli Studi di Urbino Carlo Bo, China Pharmaceutical University, Tom's of Maine, VU University Amsterdam, University of Bath, Janssen Research Foundation, TBA, Universite Libre de Bruxelles, Mayo Foundation, R.W. Johnson Pharmaceutical Research Institute, Institute of Organic Synthesis, AstraZeneca, Schering-Plough Research, University of Cambridge] 1
- [Mayo Foundation for Medical Education and Research and Mayo Clinic, Jagiellonian University Collegium Medicum, Pfizer Inc., Universit£ degli Studi di Urbino Carlo Bo, China Pharmaceutical University, Tom's of Maine, VU University Amsterdam, University of Bath, Janssen Research Foundation, TBA, Universite Libre de Bruxelles, Mayo Foundation, R.W. Johnson Pharmaceutical Research Institute, Institute of Organic Synthesis, AstraZeneca, Schering-Plough Research, University of Cambridge] 1
Affinity: 0.014 to 1.0E+6 nM▿
- Ki 25
- IC50 16
- Kd 1
- EC50 1
- Affinity ≤ nM
Xtal structures: 0
Docked structures: 0
Catalog Cmpds: 1